Psilocybin Market - 2026-2035

July 2026 | 36 pages | ID: PA08D93A8BF3EN
DataM Intelligence

Abstracts

Psilocybin Market reached USD $2.41 Billion in 2025 and is expected to reach USD $6.78 Billion by 2035, growing with a CAGR of 10.90% during the forecast period 2026-2035.

The Psilocybin Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Psilocybin Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Product Type

• Synthetic Psilocybin API and Drug Products
• Natural Psilocybin Products
• Biosynthetic Psilocybin
• Psilocin and Deuterated Analogs
• Formulation and Delivery Technologies
• Therapy and Integration Services
• Digital Monitoring and Training Tools.

By Application

• Treatment-Resistant Depression
• Major Depressive Disorder
• Anxiety Disorders
• Substance Use Disorders
• PTSD
• Palliative Care Distress
• Cluster Headache and Other Neurological Conditions
• Research and Wellness Supervised Use

By End-User

• Pharmaceutical and Biotechnology Companies
• Clinical Research Organizations
• Hospitals and Academic Medical Centers
• Specialty Psychedelic Clinics
• Licensed Psilocybin Service Centers
• Mental Health Providers
• Contract Manufacturers
• Research Institutes.

By Source

• Synthetic
• Natural
• Biosynthetic
• Semi Synthetic Analogs.

By Route/Delivery Model

• Oral Supervised Therapy
• Adjunctive Psychotherapy Model
• Service Center Administration
• Clinical Trial Administration
• Digital Supported Hybrid Care.

Regional Analysis for Psilocybin Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Psilocybin Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Data
  1.1.1. Secondary Data
  1.1.2. Primary Data
  1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
  1.2.1. Bottom-Up Approach
  1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations

2. DEFINITION AND OVERVIEW

2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period

3. EXECUTIVE SUMMARY

3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Strong Late-Stage Clinical Evidence Supporting Regulatory Progress and Commercialization
    4.1.1.2. Growing Unmet Need for Innovative Mental Health Treatments
  4.1.2. Restraints
    4.1.2.1. Stringent Regulatory Restrictions and Controlled Substance Classification
    4.1.2.2. Limited Clinical Infrastructure and Shortage of Trained Therapy Providers
  4.1.3. Impact Analysis - Drivers and Restraints
  4.1.4. Opportunity
    4.1.4.1. Expansion of Regulatory Pathways and Commercial Launch Opportunities
    4.1.4.2. Growth of Integrated Psychedelic Care and Digital Mental Health Ecosystems
  4.1.5. Trends
  4.1.6. Challenges

5. INDUSTRY ANALYSIS

5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors
  5.3.1. Rising Public Awareness and Acceptance of Mental Health Treatment
  5.3.2. Expanding Therapist Training and Patient Education Initiatives
5.4. Economic Factors
  5.4.1. Increasing Investment in Psychedelic Drug Development and Mental Healthcare
  5.4.2. High Treatment Costs and Reimbursement Uncertainty
5.5. Technological Factors
5.6. Geopolitical Factors
5.7. Supply/Value Chain Analysis
5.8. Pricing Analysis
5.9. Regulatory Analysis
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Tariff Analysis
  5.15.1. Overview Of Relevant Tariffs
  5.15.2. Trade Policies Influencing the Market
  5.15.3. Cost Impact Factors
  5.15.4. Supply Chain Disruptions
5.16. Trade Analysis - Export-Import Scenario
5.17. Business Models Analysis
5.18. Demand-Supply Gap
5.19. Risk Mitigation Framework
5.20. Compliance Roadmap
5.21. Strategic Implications
5.22. Emerging Opportunities
5.23. Adoption Trends
5.24. Disruption Analysis
5.25. DMI Opinion

6. BY PRODUCT TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  6.1.2. Market Attractiveness Index, By Product Type
6.2. Synthetic Psilocybin API and Drug Products
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Natural Psilocybin Products
6.4. Biosynthetic Psilocybin
6.5. Psilocin and Deuterated Analogs
6.6. Formulation and Delivery Technologies
6.7. Therapy and Integration Services
6.8. Digital Monitoring and Training Tools.

7. BY APPLICATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis, By Application
  7.1.2. Market Attractiveness Index, By Application
7.2. Treatment-Resistant Depression
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Major Depressive Disorder
7.4. Anxiety Disorders
7.5. Substance Use Disorders
7.6. PTSD
7.7. Palliative Care Distress
7.8. Cluster Headache and Other Neurological Conditions
7.9. Research and Wellness Supervised Use

8. BY END-USER

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  8.1.2. Market Attractiveness Index, By End-User
8.2. Pharmaceutical and Biotechnology Companies
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Clinical Research Organizations
8.4. Hospitals and Academic Medical Centers
8.5. Specialty Psychedelic Clinics
8.6. Licensed Psilocybin Service Centers
8.7. Mental Health Providers
8.8. Contract Manufacturers
8.9. Research Institutes.

9. BY SOURCE

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  9.1.2. Market Attractiveness Index, By Source
9.2. Synthetic
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Natural
9.4. Biosynthetic
9.5. Semi Synthetic Analogs.

10. BY ROUTE/DELIVERY MODEL

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route/Delivery Model
  10.1.2. Market Attractiveness Index, By Route/Delivery Model
10.2. Oral Supervised Therapy
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Adjunctive Psychotherapy Model
10.4. Service Center Administration
10.5. Clinical Trial Administration
10.6. Digital Supported Hybrid Care.

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route/Delivery Model
  11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.8.1. U.S.
    11.2.8.2. Canada
    11.2.8.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route/Delivery Model
  11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.8.1. Germany
    11.3.8.2. UK
    11.3.8.3. France
    11.3.8.4. Russia
    11.3.8.5. Spain
    11.3.8.6. Italy
    11.3.8.7. Poland
    11.3.8.8. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route/Delivery Model
  11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.8.1. Brazil
    11.4.8.2. Argentina
    11.4.8.3. Rest of South America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route/Delivery Model
  11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.8.1. China
    11.5.8.2. India
    11.5.8.3. Japan
    11.5.8.4. Australia
    11.5.8.5. South Korea
    11.5.8.6. Indonesia
    11.5.8.7. Malaysia
    11.5.8.8. Singapore
    11.5.8.9. Thailand
    11.5.8.10. Vietnam
    11.5.8.11. Philippines
    11.5.8.12. Taiwan
    11.5.8.13. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route/Delivery Model
  11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.6.8.1. UAE
    11.6.8.2. Saudi Arabia
    11.6.8.3. South Africa
    11.6.8.4. Israel
    11.6.8.5. Turkiye
    11.6.8.6. Nigeria
    11.6.8.7. Rest of Middle East and Africa

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Share Analysis 2025 - Global
12.3. Mergers and Acquisitions Analysis
12.4. Partner Identification Analysis
12.5. Investment & Funding Landscape
12.6. Strategic Alliances & Innovation Pipeline

13. COMPANY PROFILES

13.1. Compass Pathways
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Revenue Analysis
  13.1.4. Pricing Analysis
  13.1.5. SWOT Analysis
  13.1.6. Recent Developments
    13.1.6.1. Major Deals
    13.1.6.2. M&A
    13.1.6.3. Collaboration
    13.1.6.4. Acquisition
    13.1.6.5. Joint Ventures
    13.1.6.6. Innovations
  13.1.7. Recent News
    13.1.7.1. Events
    13.1.7.2. Conferences
    13.1.7.3. Symposiums
    13.1.7.4. Webinars
13.2. Compass Pathways
13.3. Cybin Inc.
13.4. AtaiBeckley
13.5. MindMed
13.6. Usona Institute
13.7. GH Research
13.8. Filament Health
13.9. Psyence Biomedical
13.10. Numinus Wellness
13.11. Silo Pharma (LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us